Literature DB >> 6457917

Side effects associated with intravesical mitomycin.

I Nissenkorn, H Herrod, M S Soloway.   

Abstract

The nature and severity of side effects accompanying intravesical chemotherapy with mitomycin C were studied in 29 patients. No patient experienced systemic toxicity. Local side effects developed in 7 patients (24 per cent), and consisted of moderate cystitis in 3 and drug-related palmar desquamation, with or without generalized rash, in 4. Based on skin tests 3 of these patients were believed to have a contact dermatitis. The fourth patient had a generalized rash, in addition to palmar desquamation, that appeared after subsequent instillations of mitomycin C and the drug had to be discontinued. Careful cleansing of the hands and perineum on the day of treatment can prevent most skin reactions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6457917     DOI: 10.1016/s0022-5347(17)54642-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  [Hematogenous contact dermatitis after intravesicular instillation of mitomycin C].

Authors:  W K Peitsch; C-D Klemke; M S Michel; S Goerdt; C Bayerl
Journal:  Hautarzt       Date:  2007-03       Impact factor: 0.751

Review 2.  Intravesical chemotherapy in the United States. An overview.

Authors:  J T Spaulding
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 3.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Eosinophilic cystitis induced by mitomycin-C.

Authors:  V Ulker; E Apaydin; A Gürsan; C Ozyurt; G Kandiloğlu
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 5.  Endoscopic Management of Luminal Strictures: Beyond Dilation.

Authors:  Nader D Daoud; Hassan Ghoz; Obaie Mzaik; Himesh B Zaver; Micah McKinney; Bhaumik Brahmbhatt; Timothy Woodward
Journal:  Dig Dis Sci       Date:  2022-02-25       Impact factor: 3.199

6.  Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

Authors:  D A Tolley; T B Hargreave; P H Smith; J L Williams; K M Grigor; M K Parmar; L S Freedman; B M Uscinska
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25

Review 7.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

8.  Detecting mitomycin C in human plasma during intravesical therapy.

Authors:  K Jauhiainen
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

9.  Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity.

Authors:  Thiru Prasanna; Paul Craft; Gayathri Balasingam; Hodo Haxhimolla; Ganes Pranavan
Journal:  Front Oncol       Date:  2017-11-02       Impact factor: 6.244

10.  Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (Ialuril® Soft Gels) for the Prevention of LUTS after Intravesical Chemotherapy.

Authors:  Celeste Manfredi; Lorenzo Spirito; Francesco Paolo Calace; Raffaele Balsamo; Marco Terribile; Marco Stizzo; Lorenzo Romano; Luigi Napolitano; Gianluigi Califano; Luigi Cirillo; Giovanni Maria Fusco; Claudia Rosati; Carmelo Quattrone; Carmine Sciorio; Massimiliano Creta; Nicola Longo; Marco De Sio; Davide Arcaniolo
Journal:  Pathophysiology       Date:  2022-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.